The general management of multiple myeloma--risk factor
Togawa, A.
Nihon Rinsho. Japanese Journal of Clinical Medicine 53(3): 642-646
1995
ISSN/ISBN: 0047-1852 PMID: 7699898 Document Number: 452304
The introduction of melphalan therapy produced improvement in either response rates or survival of patients with myeloma. Since then, many attempts have been carried out to improve the results achievable with MP therapy by the use of combination chemotherapy, but no difference in survival was found. Recent efforts have evaluated dose intensification for patients with good risk factor to from the viewpoint of bone marrow ablation requiring hematopoietic stem cell support, though these approaches may be ineffective for patients with refractory myeloma.